Stryker Corporation $SYK Stock: Villere ST Denis J & Co. LLC Decreases Position

Villere ST Denis J & Co. LLC lessened its holdings in shares of Stryker Corporation (NYSE:SYK) by 2.5% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 62,862 shares of the medical technology company’s stock after selling 1,607 shares during the period. Stryker makes up approximately 1.8% of Villere ST Denis J & Co. LLC’s portfolio, making the stock its 22nd biggest holding. Villere ST Denis J & Co. LLC’s holdings in Stryker were worth $17,312,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of SYK. Bank of America Corp DE purchased a new stake in shares of Stryker during the 2nd quarter worth $1,404,284,000. Legal & General Group Plc acquired a new position in shares of Stryker during the 2nd quarter worth $707,212,000. Jupiter Topco LLC purchased a new position in shares of Stryker in the 2nd quarter valued at about $681,581,000. Corient Private Wealth LP purchased a new position in shares of Stryker in the 2nd quarter valued at about $323,035,000. Finally, Flossbach Von Storch SE acquired a new stake in shares of Stryker in the second quarter valued at about $464,506,000. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Insiders Place Their Bets

In other news, Director Ronda Stryker sold 550,000 shares of Stryker stock in a transaction dated Friday, November 6th. The shares were sold at an average price of $325.32, for a total transaction of $178,926,000.00. Following the completion of the sale, the director directly owned 1,701,375 shares in the company, valued at $553,491,315. The trade was a 24.43% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Debra King sold 826 shares of the business’s stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $336.30, for a total transaction of $277,783.80. Following the completion of the transaction, the insider directly owned 6,210 shares of the company’s stock, valued at approximately $2,088,423. This represents a 11.74% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 901,267 shares of company stock valued at $297,123,701 in the last ninety days. Insiders own 4.60% of the company’s stock.

Analyst Upgrades and Downgrades

SYK has been the topic of a number of research analyst reports. Needham & Company LLC decreased their price objective on shares of Stryker from $418.00 to $359.00 and set a “buy” rating on the stock in a report on Friday, October 30th. Evercore lifted their price target on shares of Stryker from $335.00 to $355.00 in a research report on Wednesday, October 28th. BMO Capital Markets reissued an “outperform” rating and set a $309.00 price target (down from $317.00) on shares of Stryker in a research note on Friday, October 30th. Johnson Rice cut Stryker to a “hold” rating in a report on Friday, October 30th. Finally, Barclays dropped their price objective on Stryker from $375.00 to $365.00 and set an “overweight” rating for the company in a research note on Friday, October 30th. Twenty-one research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $342.19.

Stryker Stock Down 0.1%

SYK stock opened at $325.69 on Tuesday. The company has a debt-to-equity ratio of 0.60, a current ratio of 2.18 and a quick ratio of 1.30. The company’s 50 day simple moving average is $292.26 and its 200-day simple moving average is $323.41. Stryker Corporation has a 12 month low of $267.00 and a 12 month high of $389.33. The firm has a market capitalization of $123.99 billion, a PE ratio of 34.69, a P/E/G ratio of 2.33 and a beta of 0.78.

Stryker (NYSE:SYK) last released its quarterly earnings results on Thursday, October 29th. The medical technology company reported $3.52 earnings per share for the quarter, missing the consensus estimate of $3.55 by ($0.03). Stryker had a return on equity of 23.74% and a net margin of 13.78%. The company had revenue of $6.52 billion for the quarter, compared to analysts’ expectations of $6.62 billion. During the same period in the previous year, the business posted $3.19 EPS. The business’s quarterly revenue was up 7.6% on a year-over-year basis. Equities analysts expect that Stryker Corporation will post 14.84 earnings per share for the current fiscal year.

About Stryker

Stryker is a medical technology company that develops and sells products and services for healthcare providers. Its offerings include orthopedic implants and surgical equipment, neurotechnology and spine products, and medical and surgical equipment used in hospitals and other care settings.

The company’s products also include patient-handling and emergency medical equipment, as well as instruments and technologies that support surgical procedures. Stryker serves healthcare customers in the United States and internationally.

Founded in 1941 by orthopedic surgeon Dr.